Every 10-Q that Capricor Therapeutics Inc (CAPR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CAPR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CAPR filings page.
Capricor Therapeutics, Inc. reported no revenue for the three and six months ended June 30, 2026, while significantly increasing investment in its Duchenne muscular dystrophy programs. Research and development expenses rose to $56.2 million for the first half of 2026, and general and administrative expenses to $23.5 million, leading to a six‑month net loss of $74.7 million versus $50.3 million a year earlier.
Cash, cash equivalents and marketable securities totaled $237.9 million at June 30, 2026, down from $318.1 million at year‑end, reflecting operating cash use of $60.7 million and heavy investment in marketable securities and manufacturing and facility build‑out. The company recorded operating lease right‑of‑use assets of $88.6 million and lease liabilities of $91.0 million, driven by a long‑term San Diego headquarters and manufacturing lease. Capricor fully repaid a $6.3 million CIRM loan and continues to defer the $12.0 million Japan distribution upfront payment as deferred revenue pending future performance obligations.
Capricor Therapeutics (CAPR) filed its Q3 2025 10‑Q, reporting a net loss of $24.6 million and stating “substantial doubt” about its ability to continue as a going concern. Revenue was $0 in the quarter (vs. $2.3 million a year ago) as prior-period milestone activity did not recur. Operating expenses rose to $26.3 million, led by research and development of $20.4 million and general and administrative of $5.9 million.
Cash and cash equivalents were $19.5 million and marketable securities were $79.1 million, for approximately $98.6 million in total liquid resources at September 30, 2025. Net cash used in operating activities was $46.2 million for the nine months. Stockholders’ equity was $83.9 million, down from $145.5 million at year‑end. The company elected to convert a prior CIRM award into a loan; the principal was about $3.4 million as of quarter‑end.
CAPR established a new at‑the‑market facility of up to $150 million in September 2025; no shares had been sold under this program as of the report date. Weighted-average basic and diluted shares were 45.7 million, and 45,718,475 shares were outstanding as of November 7, 2025.
Capricor Therapeutics, Inc. (CAPR) reported total assets of $133.6 million and held approximately $122.8 million in combined cash, cash equivalents and marketable securities as of June 30, 2025. Marketable securities declined to $99.56 million from $140.23 million at year-end 2024 while cash and cash equivalents increased to $23.24 million from $11.29 million. Total stockholders' equity was $104.98 million and the accumulated deficit grew to approximately $250.1 million.
The company recorded a net loss of $25.9 million for the three months ended June 30, 2025 and $50.3 million for the six months ended June 30, 2025, driven by higher research and development expense ($22.0 million in the quarter; $41.0 million for six months) and increased general and administrative costs. The filing discloses conversion of a CIRM grant to a proposed loan with potential accrued interest up to about $7.1 million and notes recent securities and derivative lawsuits filed in July and August 2025. The company states it will require substantial additional capital to fund operations and may seek equity, debt, partnerships, or government grants.